scout

Hossein Borghaei, DO, MS, Fox Chase Cancer Center

Articles by Hossein Borghaei, DO, MS, Fox Chase Cancer Center

Future Directions in Treatment of Small Cell Lung Cancer

ByHossein Borghaei, DO, MS, Fox Chase Cancer Center,Anne Chiang, MD, PhD, Yale Cancer Center,Wade Iams, MD, Vanderbilt University Medical Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Vivek Subbiah, MD, MD Anderson Cancer Center

Panelists conclude their discussion by commenting on areas of unmet need and sharing personal perspectives on factors that may change clinical practice for SCLC in the future.

Emerging Treatments in SCLC: Triplets + Limited-Stage Disease

ByHossein Borghaei, DO, MS, Fox Chase Cancer Center,Anne Chiang, MD, PhD, Yale Cancer Center,Wade Iams, MD, Vanderbilt University Medical Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Vivek Subbiah, MD, MD Anderson Cancer Center

Anne Chiang, MD, PhD, reviews the study design of 2 clinical trials, adding a third agent to the standard-of-care regimen of chemotherapy plus I/O; Stephen Liu, MD, discusses clinical trials in limited-stage disease.

Treatment Considerations: Chemotherapy + IO in ES SCLC

ByHossein Borghaei, DO, MS, Fox Chase Cancer Center,Anne Chiang, MD, PhD, Yale Cancer Center,Wade Iams, MD, Vanderbilt University Medical Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Vivek Subbiah, MD, MD Anderson Cancer Center

Panelists reflect on key points from recent studies in ES SCLC by discussing patients for whom immunotherapy may be appropriate, examining the role of adding CTLA4 inhibition to a PD-L1 inhibitor, and reviewing factors to consider when deciding between cisplatin or carboplatin.

First-Line Therapy in ES SCLC: CASPIAN

ByHossein Borghaei, DO, MS, Fox Chase Cancer Center,Anne Chiang, MD, PhD, Yale Cancer Center,Wade Iams, MD, Vanderbilt University Medical Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Vivek Subbiah, MD, MD Anderson Cancer Center

Thoracic oncologist, Anne Chiang, MD, PhD, reviews the trial design and results of the CASPIAN trial and emphasizes implications for long-term benefit of combining platinum chemotherapy with durvalumab.

First-Line Therapy in ES SCLC: IMpower133

ByHossein Borghaei, DO, MS, Fox Chase Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Vivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale Cancer Center,Wade Iams, MD, Vanderbilt University Medical Center

Stephen Liu, MD guides a discussion on recent updates on IO+chemotherapy combinations in extensive-stage small cell lung cancer by reviewing data from the phase 3 IMpower133 l trial of carboplatin/etoposide/atezolizumab.

Latest Updated Articles